MetLife's underwriting and investment engines both improved in the second quarter, but almost none of that reached the GAAP bottom line. Adjusted earnings — the company's own segment-performance measure — rose 15.1% to $1,604 million, while net income attributable to MetLife crept up just 1.0% to $736 million, leaving an $868 million gap between the two. The largest component of that wedge is $1,200 million of combined net investment losses ($428 million) and net derivative losses ($772 million), the accounting shadow of hedging a liability book that is not marked to market alongside it; the remaining items — MRB remeasurement gains of $270 million, investment hedge adjustments of −$170 million, real-estate and REJV depreciation of −$54 million, other items of +$95 million, a tax benefit of $234 million, and a noncontrolling-interest deduction of $43 million — net to +$332 million, and $1,200 million less $332 million accounts for the full $868 million divergence. For an insurer, the question is not which number is "correct" but which one predicts next year's cash — and on that test the operating detail matters more than the headline.
The market took the same view. On the company's own measure, adjusted EPS rose 20% to $2.43, beating consensus of roughly $2.36, and adjusted return on equity reached 17.0% — the top of MetLife's 15–17% target range. Total revenue of $19.15 billion, by contrast, fell short of the roughly $19.68 billion analysts expected. Investors sided with the earnings line: the stock rose about 3.7% to $99.78, near its 52-week high. (Adjusted EPS, adjusted ROE, variable investment income and buyback figures cited in this article come from MetLife's Q2 2026 earnings release and August 2026 earnings call; all balance-sheet, income-statement and cash-flow figures are from the Q2 2026 Form 10-Q.)
1. Balance Sheet: Deposits Grow, Equity Shrinks
1-1. Principal Asset Items
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % |
|---|---|---|---|
| Fixed maturity securities AFS | 315,931 | 322,183 | +2.0% |
| Mortgage loans | 84,593 | 82,856 | −2.1% |
| Short-term investments | 3,601 | 8,016 | +122.6% |
| Total investments | 472,178 | 482,563 | +2.2% |
| Cash and cash equivalents | 22,032 | 19,301 | −12.4% |
| Premiums, reinsurance and other receivables | 49,059 | 50,635 | +3.2% |
| DAC and VOBA | 21,107 | 21,571 | +2.2% |
| Goodwill | 9,613 | 9,536 | −0.8% |
| Separate account assets | 151,933 | 156,850 | +3.2% |
| Total assets | 745,166 | 759,372 | +1.9% |
The most informative line is the one investors rarely read: amortized cost on the AFS portfolio is $347,781 million against $322,183 million of fair value, an unrealized loss position of $25,598 million that widened from $21,270 million at year-end — $4,328 million of additional mark-to-market pain in six months. Because these are available-for-sale securities held against long-dated liabilities, the loss sits in other comprehensive income rather than earnings, and it reverses as bonds pull to par. But it is the direct reason book value is falling while earnings rise.
Short-term investments more than doubled to $8,016 million while cash fell $2,731 million — a reallocation within liquidity rather than a change in it. The allowance for credit loss on mortgage loans rose to $1,358 million from $1,193 million, a 13.8% increase against a shrinking loan book, which is the one genuine credit signal in the asset table and bears watching in commercial real estate.
On the liability side, policyholder account balances grew 3.6% to $245,458 million while future policy benefits fell 1.3% to $206,150 million. The FPB decline is not lapsation: the Asia whole and term life rollforward shows the PV of Expected FPBs contracting by $2,510 million from changes in discount rate assumptions and by $637 million from foreign currency translation, compressing the net FPB liability from $11,844 million to $8,565 million year over year. The PV of Expected Net Premiums side also declined — by $528 million on discount rate assumptions and $148 million on currency — partially offsetting the liability reduction, with the residual movement coming from interest accretion, new business and cash flows. Higher discount rates and a weaker yen are the two primary channels through which the reported liability was compressed. Total debt (short-term, long-term, collateral financing and subordinated) rose modestly to $20,134 million from $19,329 million, driven by $1,000 million of subordinated debt issued in the half — subordinated securities alone are up 23.8% to $5,144 million, a deliberate shift toward capital-efficient hybrid funding.
1-2. Capital Structure
Total MetLife stockholders' equity fell 3.4% to $27,441 million. The roll-forward reconciles exactly: $28,398 million opening, plus $1,921 million of net income attributable, less $76 million preferred and $755 million common dividends, less $1,463 million of treasury stock, less $659 million of OCI deterioration, plus $75 million of paid-in capital. Two of those six items — buybacks and OCI — together came to $2,122 million and outweighed a profitable half-year.
Book value per common share was $38.47, down from $38.90. Excluding AOCI, the measure management and most analysts actually use, it rose to $67.86 from $66.50 — a 2.0% gain over the six-month period when reported book value fell. (All four per-share figures are derived by subtracting preferred liquidation preference of $2,905 million from total equity, adding back accumulated other comprehensive loss, and dividing by shares outstanding; they are not directly disclosed in the 10-Q.) That divergence is the entire MetLife capital story in one line, and it is why AOCI-inclusive book value is a poor yardstick for a liability-driven balance sheet under US GAAP, where the liabilities are not fair-valued in tandem with the bonds backing them.
2. Income Statement: The Recurring Portfolio, Not a Windfall
2-1. Second-Quarter Results
| Item | Q2 2025 ($M) | Q2 2026 ($M) | Change % |
|---|---|---|---|
| Premiums | 10,810 | 11,435 | +5.8% |
| Universal life and investment-type policy fees | 1,259 | 1,372 | +9.0% |
| Net investment income | 5,661 | 6,702 | +18.4% |
| Net investment gains (losses) | (273) | (428) | — |
| Net derivative gains (losses) | (796) | (772) | — |
| Total revenues | 17,340 | 19,154 | +10.5% |
| Policyholder benefits and claims | 10,767 | 11,335 | +5.3% |
| Interest credited to PABs | 2,400 | 3,067 | +27.8% |
| Other expenses | 3,319 | 3,844 | +15.8% |
| Net income attributable to MetLife | 729 | 736 | +1.0% |
| Adjusted earnings | 1,393 | 1,604 | +15.1% |
| Diluted EPS (GAAP) | $1.03 | $1.09 | +5.8% |
| Adjusted EPS (company measure) | — | $2.43 | +20% |
Net investment income of $6,702 million is the highest in the series disclosed here. Figures directly verifiable from the 10-Q or company releases show: $4,885 million in Q1 2025, $5,661 million in Q2 2025, approximately $5.9 billion in Q4 2025 (per MetLife's February 4, 2026 earnings release), $5,355 million in Q1 2026, and $6,702 million in Q2 2026. Note that beginning in Q4 2025, MetLife's definition of net investment income excludes depreciation of wholly-owned real estate and real-estate joint ventures, so direct comparisons with earlier quarters require adjustment.
The instinct is to attribute a swing of that size to variable investment income — private equity and other limited partnership returns that are marked through income and do not annualize. In this quarter that instinct is wrong, and the correction cuts in the company's favor. MetLife disclosed variable investment income of $231 million pre-tax in Q2 2026, well short of its own roughly $400 million quarterly guidance — a headwind of some $170 million, not a windfall. The 18.4% increase in net investment income therefore came from the recurring book: a larger invested asset base, up 2.2% in six months, reinvesting maturities at higher yields. That is a materially more durable source of earnings than an alternatives spike, and it is the single most important earnings-quality point in the quarter. Asia's mix shift — equity-method assets supplied 12% of that segment's net investment income this quarter versus 10% a year ago, and 15% versus 10% for the half — shows where alternatives exposure is concentrated, but at a consolidated $231 million those assets were a drag on the result rather than the engine of it. The corollary is that a normalization of variable investment income back toward guidance would be a tailwind from here, not a cliff.
The offset is equally large. Interest credited to policyholder account balances rose 27.8% to $3,067 million, faster than investment income itself, because the deposit-type book is repricing toward higher crediting rates. The net spread — investment income less interest credited — was $3,635 million against $3,261 million, up 11.5%. That is the honest read on the investment result: strong, but roughly two-thirds of the gross gain was passed through to policyholders.
Six-month figures show the same shape with less noise: revenues +6.5% to $38,228 million, net income attributable to MetLife +14.4% to $1,921 million, diluted EPS +22.0% to $2.83. EPS outran net income available to common (+17.0%) by roughly five percentage points on a shrinking share count — but the two share measures must not be confused. Shares outstanding fell 2.7% to 637.8 million between year-end and June 30; the weighted-average diluted count that actually drives EPS fell about 4.4% year over year (roughly 652 million versus 682 million, derived from reported earnings and EPS). It is the latter, not the period-end figure, that accounts for the gap.
2-2. Where the Earnings Came From
| Segment | Q2 2025 adj. earnings ($M) | Q2 2026 ($M) | Change % | Q2 revenue growth |
|---|---|---|---|---|
| Group Benefits | 401 | 503 | +25.4% | +1.1% |
| Retirement and Income Solutions | 370 | 377 | +1.9% | +12.4% |
| Asia | 346 | 420 | +21.4% | +5.9% |
| Latin America | 233 | 268 | +15.0% | +19.6% |
| EMEA | 100 | 108 | +8.0% | +11.9% |
| MetLife Investment Management | 54 | 57 | +5.6% | +33.5% |
| Total segment | 1,504 | 1,733 | +15.2% | +7.8% |
| Corporate & Other | (111) | (129) | — | — |
| Total adjusted earnings | 1,393 | 1,604 | +15.1% |
Group Benefits produced the largest dollar gain — $102 million — on revenue growth of just 1.1%. That is pure margin: policyholder benefits, claims and dividends fell to $5,053 million from $5,161 million even as premiums edged up to $5,819 million from $5,801 million, taking the benefit-to-premium ratio to 86.8% from 89.0% — a 2.1-point improvement. A move of that size in the largest US group book is worth more to earnings than any top-line story elsewhere in the company, and favorable mortality and morbidity of this magnitude is inherently period-specific.
The contrast with RIS is instructive. RIS grew revenue 12.4% but adjusted earnings only 1.9%. Most of the $440 million revenue gain was driven by premiums rising from $1,210 million to $1,587 million, while policyholder benefits and dividends climbed from $2,045 million to $2,466 million — a $421 million increase that absorbed nearly all of the top-line gain. On the investment side, the spread — $2,219 million of net investment income less $908 million of interest credited — was $1,311 million, up 3.8% from $1,263 million a year earlier: volume growing at thin incremental margin. Latin America was the cleanest result, converting 19.6% revenue growth into 15.0% earnings growth. MIM's 33.5% revenue jump reflects the PineBridge Investments acquisition completed in Q4 2025 for a preliminary $885 million, but $133 million of its quarterly revenue is intersegment asset management fees — a consolidation elimination, not third-party money.
Corporate & Other, which now houses the run-off long-term care and legacy annuity blocks following the Q4 2025 Strategic Reorganization that retired the MetLife Holdings segment, widened its loss to $129 million from $111 million.
3. Cash Flow: Operating Cash Down, Deposits Up
| Item (six months) | 2025 ($M) | 2026 ($M) | Change |
|---|---|---|---|
| Operating activities | 6,449 | 4,915 | −23.8% |
| Investing activities | (6,303) | (14,326) | −8,023 |
| Financing activities | 1,669 | 6,775 | +5,106 |
| Cash, end of period | 22,178 | 19,301 | −12.9% |
Free cash flow is not a meaningful construct for a life insurer, whose investing line is portfolio churn rather than capacity expansion. The relevant substitute is net deposit flow: policyholder account deposits of $57,020 million against withdrawals of $50,094 million produced $6,926 million of net inflow, up from $4,087 million a year earlier. That $2.8 billion improvement is what funded the enlarged investing outflow, and it is a genuine franchise indicator — customers are adding money faster than they are taking it out.
The 23.8% decline in operating cash flow to $4,915 million deserves scrutiny against $1,941 million of consolidated net income. At 2.5 times, the cash conversion ratio remains comfortably above 1.0x, so this is not an earnings-quality warning. Separately, the sharp widening in investing outflows — from $6,303 million to $14,326 million — partly reflects freestanding derivative activity: $2,743 million was paid versus $1,091 million received, a $1,652 million net drain through investing activities, up from $521 million in the prior-year half, reflecting the real economic cost of the hedging program.
Financing inflows of $6,775 million included $1,000 million of subordinated debt securities issued and $843 million of proceeds from notes issued by collateralized financing entities — against nil in the prior-year half, making the latter a new funding channel rather than a repeat item, and partly offset by $537 million of repayments on those same notes. Against the inflows ran $1,477 million of treasury stock acquired in share repurchases, $755 million of common dividends and $76 million of preferred dividends. Worth noting: the repurchase spend was lower than the prior-year half's $1,921 million, so the equity erosion described in Section 1-2 came from a decelerating buyback, not an accelerating one.
4. What to Watch
The board approved a new $3.0 billion common stock repurchase authorization on August 5, 2026, and the company returned roughly $1.1 billion to shareholders during the quarter, including about $700 million of buybacks. Read against Section 1-2, that authorization is the crux of the MetLife equity story: management is committing to shrink the share count further at a time when AOCI is already suppressing reported book value. The result will be continued pressure on GAAP book value per share alongside continued support for EPS and for the ex-AOCI measure — precisely the divergence this quarter put on display.
Three things determine whether the 17.0% adjusted ROE holds. First, whether Group Benefits' 2.1-point underwriting improvement persists or reverts, since favorable mortality and morbidity of that magnitude does not repeat on schedule. Second, whether variable investment income recovers from $231 million toward the $400 million quarterly guidance — a gap that, unusually, represents upside rather than a risk of giving something back. Third, whether the crediting-rate repricing that consumed two-thirds of the gross investment income gain continues to widen, which would cap spread income even as the invested asset base grows.
The revenue miss against consensus matters less than it looks. MetLife's top line carries net investment and derivative losses through it, so a quarter with $1,200 million of those marks will miss a revenue forecast almost mechanically while the operating engine performs. That is the same wedge described at the top of this article, arriving in a different disguise.
This article is journalism, not investment advice. LineVest News is not a registered investment adviser.